Remunity Pump on Market for Dispensing Remodulin

Teresa Carvalho avatar

by Teresa Carvalho |

Share this article:

Share article via email
Remunity pump for PAH

Remunity, an innovative pump for Remodulin (treprostinil) to treat adults with pulmonary arterial hypertension (PAH), has launched commercial sales, according to the device’s developer, United Therapeutics.

The Remunity system allows constant subcutaneous (under-the-skin) delivery of Remodulin (treprostinil). The therapy mimics the effects of prostacyclin, a natural vasodilator that helps blood vessels widen, improving blood flow and preventing blockage in arteries.

“We are excited to bring to market the first subcutaneous pump designed specifically for PAH patients,” Beth Rhodes, vice president of global supply chain and alliance management at United Therapeutics, said in a press release.

Remunity is a small pump that is connected to a non-reusable cassette containing up to three days of medication. The pump has a service life of three years before it needs to be replaced.

The prefilled cassettes “are delivered directly to patients, offering significant improvements over current subcutaneous pumps,” Rhodes said.

The system was approved by the U.S. Food and Drug Administration in 2019 with instructions for patients to fill the pump. In 2020, an additional clearance allowed specialty pharmacies to prefill cassettes with Remodulin, offering a more precise and convenient method for people with PAH.

Remunity is water resistant and can be programmed wirelessly by a separate and small remote, making it safer and easier to use.

The system also provides a broader range of notifications, alerts and alarms, compared to other pumps. It contains acoustic volume-sensing technology and a solid-state actuator, enabling control of Remodulin flow rates without using a motor.

Developed together with DEKA Research & Development, the Remunity system is indicated for the treatment of PAH patients 22 and older.

“While the COVID-19 pandemic has been devastating to all of us, the DEKA team has never forgotten that the PAH community is particularly vulnerable,” said Dean Kamen, founder and president of DEKA.

“This stark reality, along with the unwavering commitment by the UT [United Therapeutics] team, has continued to energize us to reach this significant goal. We are confident that the Remunity Pump, particularly with cassettes prefilled with Remodulin, has the potential to improve the lives of the patients,” Kamen said.